FDA Reversal Opens $4B US Market for Moderna's mRNA-1010 Flu Vaccine
Moderna secured FDA agreement to review its mRNA-1010 seasonal flu vaccine candidate after the agency initially refused a submission, reopening access to a $4B US influenza market. The reversal could advance a 2026 launch and materially expand Moderna's post-COVID revenue stream.
1. FDA Reversal on mRNA-1010 Review
Moderna submitted its biologics license application for mRNA-1010 earlier this year but faced an unexpected refusal from the FDA. In February 2026, the agency reversed its decision and agreed to accept the application for full review, restoring the regulatory pathway toward approval.
2. Potential US Influenza Market Opportunity
The US seasonal influenza market is valued at approximately $4 billion annually, dominated by legacy manufacturers. Approval of mRNA-1010 would allow Moderna to compete with existing quadrivalent vaccines and potentially command premium pricing based on mRNA technology benefits.
3. Projected Launch Timeline and Revenue Impact
With the FDA now reviewing the application under its standard six-month timeline, Moderna is targeting a mid-2026 commercial launch. A successful approval could generate significant non-COVID revenue, diversify Moderna's pipeline and influence its stock valuation ahead of next year’s flu season.